Neovasc Inc. (NASDAQ:NVCN) is scheduled to post its Q216 quarterly earnings results on Monday, November 14th. Analysts expect Neovasc to post earnings of ($0.09) per share and revenue of $2.20 million for the quarter.

Shares of Neovasc Inc. (NASDAQ:NVCN) opened at 0.5205 on Friday. The firm has a 50-day moving average of $0.55 and a 200 day moving average of $0.83. The company’s market cap is $34.80 million. Neovasc Inc. has a one year low of $0.37 and a one year high of $5.04.

A hedge fund recently raised its stake in Neovasc stock. Capital World Investors raised its stake in shares of Neovasc Inc. (NASDAQ:NVCN) by 5.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,345,736 shares of the company’s stock after buying an additional 261,443 shares during the period. Capital World Investors owned 8.00% of Neovasc worth $2,808,000 as of its most recent filing with the SEC. 23.30% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research raised shares of Neovasc from a “sell” rating to a “hold” rating in a research note on Thursday, July 14th.

About Neovasc

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

5 Day Chart for NASDAQ:NVCN

Receive News & Stock Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related stocks with our FREE daily email newsletter.